Köllensperger M, Geser F, Seppi K, Stampfer-Kountchev M, et al. Red flags for multiple system atrophy. Mov Disord. 2008 Jun 15;23(8):1093-9.
Abele M, Minnerop M, Urbach H, Specht K, Klockgether T. Sporadic adult onset ataxia of unknown etiology : a clinical, electrophysiological and imaging study. J Neurol. 2007 Oct;254(10):1384-9.
Weyer A, Abele M, Schmitz-Hübsch T, Schoch B, Frings M, Timmann D, Klockgether T. Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Mov Disord. 2007 Aug 15;22(11):1633-7.
Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light the-rapy in Parkinson's disease: a pilot study. Mov Disord. 2007 Jul 30;22(10):1495-8.
Minnerop M, Specht K, Ruhlmann J, Schimke N, Abele M, Weyer A, Wüllner U, Klockge-ther T. Voxel-based morphometry and voxel-based relaxometry in multiple system at-rophy-a comparison between clinical subtypes and correlations with clinical parame-ters. Neuroimage. 2007 Jul 15;36(4):1086-95.
Wüllner U, Schmitz-Hübsch T, Abele M, Antony G, Bauer P, Eggert K. Features of pro-bable multiple system atrophy patients identified among 4770 patients with parkinso-nism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. J Neural Transm. 2007 Sep;114(9):1161-5.
Abele M, Klockgether T. Health related quality of life in sporadic adult onset ataxia. Mov Disord. 2007;22(3):348-52.
Weyer A, Minnerop M, Abele M, Klockgether T. REM sleep behavioral disorder in pure autonomic failure (PAF). Neurology. 2006 Feb 28;66(4):608-9.
Schrag A, Geser F, Stampfer-Kountchev M, Seppi K, et al. European MSA-Study Group. Health-related quality of life in multiple system atrophy. Mov Disord. 2006 Jun;21(6):809-15
10. Klebe S, Durr A, Rentschler A, Hahn-Barma V, et al. New mutations in protein kinase
Cgamma associated with spinocerebellar ataxia type 14. Ann Neurol. 2005 Nov;58(5):720-9.
11. Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, et al. The European MSA Study
Group. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord. 2006 Feb;21(2):179-86.
12. Wüllner U, Reimold M, Abele M, Bürk K, et al. Dopamine Transporter PET in Spinoce-
rebellar Ataxias Type 1, 2, 3 and 6. Arch Neurol. 2005;62(8):1280-5.
13. Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, et al. The European Multiple
System Atrophy-Study Group (EMSA-SG). J Neural Transm. 2005;112(12):1677-86.
14. Seifried C, Velázquez-Pérez L, Santos-Falcón N, Abele M, et al. Saccade velocity as a sur-
rogate disease marker in spinocerebellar ataxia type 2. Ann NY Acad Sci. 2005;1039:524-7.
15. Schöls L, Zange J, Abele M, Schillings M, et al. L-carnitine and creatine in Friedreich's
ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm. 2005;112:789-96.
16. Velázquez-Pérez L, Seifried C, Santos-Falcón N, Abele M, et al. Saccade velocity is con-
trolled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol. 2004;56:444-7.
17. Abele M, Klockgether T, Wüllner U. Spectral analysis of heart rate variability in multiple
system atrophy and unexplained sporadic ataxia. J Neurol. 2004;251(7):894-5.
18. Wüllner U, Abele M, Schmitz-Huebsch T, Wilhelm K, et al. Probable multiple system at-
rophy in a German family. JNNP. 2004;75(6):924-5.
19. Specht K , Minnerop M, Abele M, Reul J, Wüllner U, Klockgether T. In vivo voxel-based
morphometry in multiple system atrophy of cerebellar type (MSA-C). Arch Neurol. 2003;60(10):1431-5.
20. Abele M, Riet A, Klockgether T, Wüllner U. Olfactory dysfunction in cerebellar ataxia
and multiple system atrophy. J Neurol. 2003;250:1453-5.
21. Abele M, Schöls L, Schwartz S, Klockgether T. Prevalence of antigliadin antibodies in a-
taxia patients. Neurology. 2003 May 27;60(10):1674-5.
22. Abele M, Bürk K, Schöls L, Schwartz S, et al. The aetiology of sporadic adult-onset ata-
23. Abele M, Bürk K, Laccone F, Dichgans J, Klockgether T. Restless legs syndrome in spino-
cerebellar ataxia types 1, 2, and 3. J Neurol. 2001 Apr;248(4):311-4.
24. Abele M, Schulz JB, Bürk K, Topka H, Dichgans J, Klockgether T. Nerve conduction stu-
dies in multiple system atrophy. Eur Neurol. 2000;43(4):221-3.
25. Abele M, Schulz JB, Bürk K, Topka H, Dichgans J, Klockgether T. Evoked potentials in
multiple system atrophy (MSA). Acta Neurol Scand. 2000 Feb;101(2):111-5.
26. Bürk K, Fetter M, Abele M, Laccone F, et al. Autosomal dominant cerebellar ataxia type
I: oculomotor abnormalities in families with SCA1, SCA2, and SCA3. J Neurol. 1999 Sep;246(9):789-97.
27. Leonhardt M, Abele M, Klockgether T, Dichgans J, Weller M. Pathological yawning
(chasm) associated with periodic leg movements in sleep: cure by levodopa. J Neurol. 1999 Jul;246(7):621-2.
28. Bürk K, Globas C, Bosch S, Gräber S, et al. Cognitive deficits in spinocerebellar ataxia
29. Abele M, Weller M, Mescheriakov S, Bürk K, Dichgans J, Klockgether T. Cerebellar ataxia
with glutamic acid decarboxylase autoantibodies. Neurology. 1999 Mar 10;52(4):857-9.
30. Klockgether T, Schöls L, Abele M, Bürk K, et al. Age related axonal neuropathy in spino-
cerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD). J Neurol Neurosurg Psy-chiatry. 1999 Feb;66(2):222-4.
31. Schulz JB, Skalej M, Wedekind D, Luft AR, et al. Magnetic resonance imaging-based vo-
lumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol. 1999 Jan;45(1):65-74.
32. Klockgether T, Skalej M, Wedekind D, Luft AR, et al. Autosomal dominant cerebellar a-
taxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spi-nocerebellar ataxia types 1, 2 and 3. Brain. 1998;121:1687-93.
33. Abele M, Leonhardt M, Dichgans J, Weller M. CCNU overdose during PCV chemothe-
rapy for anaplastic astrocytoma. J Neurol. 1998 Apr;245(4):236-8.
34. Klockgether T, Ludtke R, Kramer B, Abele M, et al. The natural history of degenerative
ataxia: a retrospective study in 466 patients. Brain. 1998;121:589-600.
35. Abele M, Bürk K, Andres F, Topka H, et al. Autosomal dominant cerebellar ataxia type I.
Nerve conduction and evoked potential studies in families with SCA1, SCA2 and SCA3. Brain. 1997:2141-8.
36. Bürk K, Stevanin G, Didierjean O, Cancel G, et al. Clinical and genetic analysis of three
German kindreds with autosomal dominant cerebellar ataxia type I linked to the SCA2 locus. J Neurol. 1997 Apr;244(4):256-61.
37. Bürk K, Abele M, Fetter M, Dichgans J, et al. Autosomal dominant cerebellar ataxia type
I clinical features and MRI in families with SCA1, SCA2 and SCA3. Brain. 1996;119:1497-505.
Abele M. Quality of Life in Sporadic Adult-Onset Staxia. In: Handbook of Disease Bur-dens. Springer Verlag Berlin Heidelberg. (in press)
Abele M, Klockgether T. Ataxien. In: Bewegungsstörungen. Thieme Verlag Stuttgart, Hrsg. Ceballos-Baumann A. und Conrad B. 2. Aufl. 2005.
Klockgether T, Abele M. Hereditary ataxias. In: Clinical Neurophysiology of Motor Neu-ron Diseases. Elsevier Amsterdam, Edited by Andrew Eisen. 2004.
Fu YH, Abele M, Ptácek LJ. Spinocerebellar Ataxia Type 4. In: Handbook of ataxia disor-ders. Marcel Dekker, Inc. Edited by Thomas Klockgether. 2000.
Abele M. Ataxia Due to Physical Causes. In: Handbook of ataxia disorders. Marcel Dek-ker, Inc. Edited by Thomas Klockgether. 2000.
Mechanism-based Drug Design in the Coward Research Group: From Felicia Wu to the Present Departments of Medicinal Chemistry & Chemistry, University of Michigan, Ann Arbor, MI 48109 USA. Correspondence e-mail address: jkcoward@umich.edu This lecture, in memory of Felicia Ying-Hsieuh Wu, will include representative examples of mechanism-based drug discovery efforts that have been pu
How many soil water content TION NOTE measurements are enough? Copyright (C) 2001Campbell Scientific, Inc. How many soil water content measurements are enough? This application note provides basic statistical methods used to determine the number ofmeasurements needed to provide a specific level of confidence that the soil water con-tent of a given area has been adequately chara